WHO Public Assessment Reports (WHOPARs) published
M
Active Pharmaceutical Ingredient (API) Prequalified
M
Rifampicin (WHOAPI-507) manufactured by Macleods Pharmaceuticals Ltd has been prequalified by the WHO Prequalification Team medicines under its API prequalification procedure.
22nd Invitation to Manufacturers and Suppliers of Medicinal Products for HIV Infections and Related Diseases to Submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Unit
M
The Invitation to Manufacturers for HIV Infections and Related Diseases to submit an Expression of Interest for Product E
Macleods’ bedaquiline tablet prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Macleods’ pretomanid tabl prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Revised NTD EOI published
M
On 29 October 2024, the revised 9th NTD EOI, now including Moxidectin, was published.
WHO grants approval for use of Bavarian Nordic’s mpox vaccine in adolescents
V
On 8 October 2024, WHO granted prequalification for the age-extension of the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine for use in adolescents aged 12 to 17 years, expanding its indi
Lupin’s isoniazid/rifapentine tablet prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list: